# US 8,771,701 B2 · Compositions for immunotherapy and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,771,701 B2
- Document ID: US8771701B2
- Status: Granted
- Kind: B2
- Application number: 11/561,204
- Filed: 2006-11-17
- Published: 2007-03-29
- Granted: 2014-07-08
- Earliest claimed: 1997-09-29
- Assignees: Macfarlane Burnet Institute for Medical Research and Public Health Limited
- Applicants: Ian F. C. McKenzie; Vasso Apostolopoulos; Geoffrey A. Pietersz
- Inventors: Ian F. C. McKenzie; Vasso Apostolopoulos; Geoffrey A. Pietersz
- Web page: https://patentgrep.com/patent/US8771701B2

## CPC

- A61K 39/385: Haptens or antigens, bound to carriers
- A61K 40/10: characterised by the cell type used
- A61K 40/17: Monocytes; Macrophages
- A61K 40/19: Dendritic cells
- A61K 40/24: Antigen-presenting cells [APC]
- A61K 40/4257: {Mucins, e.g. MUC-1}
- A61P 1/02: Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 17/00: Drugs for dermatological disorders
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 27/02: Ophthalmic agents
- A61P 31/04: Antibacterial agents
- A61P 31/16: for influenza or rhinoviruses
- A61P 31/18: for HIV
- A61P 31/20: for DNA viruses
- A61P 31/22: for herpes viruses
- A61P 33/06: Antimalarials
- A61P 35/00: Antineoplastic agents
- A61P 37/02: Immunomodulators
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- C12N 5/0645: {Macrophages, e.g. Kuepfer cells in the liver; Monocytes}
- A61K 2039/57: {characterised by the type of response, e.g. Th1, Th2}
- A61K 2039/6087: {Polysaccharides; Lipopolysaccharides [LPS]}
- C12N 2500/38: Vitamins
- C12N 2501/22: Colony stimulating factors (G-CSF, GM-CSF)
- C12N 2501/23: Interleukins [IL]
- C12N 2501/25: Tumour necrosing factors [TNF]
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The present invention relates to a method of eliciting a cytotoxic T lymphocyte response to an antigen in an animal, the method comprising pulsing mannose receptor-bearing antigen presenting cells in vitro or ex vivo with a conjugate comprising an antigen and a carbohydrate polymer comprising mannose, wherein said carbohydrate polymer is a fully oxidized carbohydrate polymer comprising free aldehydes; and administering the pulsed antigen presenting cells to an animal.

## Claims

### Claim 1

A method of eliciting a cytotoxic T lymphocyte response in an human to an antigen selected from the group consisting of a mucin polypeptide, one or more repeated subunits thereof and an antigenic fragment of said repeated subunits, said fragment comprising at least 5 amino acids of said repeated subunits, the method comprising pulsing mannose receptor-bearing antigen presenting cells in vitro or ex vivo with a conjugate comprising said antigen and a carbohydrate polymer wherein said carbohydrate polymer is a fully oxidized carbohydrate polymer comprising free aldehydes, and wherein said pulsing results in binding of said conjugate to said mannose receptor, and wherein said binding results in internalizing, processing and presenting of said antigen on said antigen presenting cells; and administering the pulsed antigen presenting cells to said human.

### Claim 2 (depends on 1)

The method of claim 1, wherein said mannose receptor-bearing antigen presenting cells are derived from a cell population selected from the group consisting of peripheral blood leukocytes, bone marrow, stem cells, peritoneal cells, spleen, lung and lymph node cells.

### Claim 3 (depends on 1)

The method of claim 1, wherein said mannose receptor-bearing antigen presenting cells are selected from the group consisting of macrophage cells and dendritic cells.

### Claim 4 (depends on 1)

The method of claim 1, wherein said mannose receptor-bearing cells comprise antigen presenting cells that express molecules selected from the group consisting of CD11b, CD14, CD68, CD80 and CD86.

### Claim 5 (depends on 1)

The method of claim 1, wherein said mannose receptor-bearing antigen presenting cells comprise cells that have been contacted with one or more biological response modifiers selected from the group consisting of a cytokine and a vitamin under conditions effective to induce expression of carbohydrate receptors by said cells.

### Claim 6 (depends on 5)

The method of claim 5, wherein said biological response modifiers induce expression of mannose receptors on said antigen presenting cell.

### Claim 7 (depends on 5)

The method of claim 5, wherein said biological response modifiers are selected from the group consisting of granulocyte macrophage colony stimulating factor (GM-CSF), interleukin-3, interleukin-4, vitamin D, macrophage colony stimulating factor (M-CSF), Flt-3 ligand and tumor necrosis factor (TNF) alpha.

### Claim 8 (depends on 1)

The method of claim 1, wherein said mucin is human mucin.

### Claim 9 (depends on 1)

The method of claim 1, wherein said antigen comprises two to eighty copies of said repeated subunits of human mucin.

### Claim 10 (depends on 1)

The method of claim 1, wherein said one or more repeated subunits of said antigen comprise part of a fusion polypeptide.